Clinical Study

Optimal Timing Of Direct Acting Antivirals In Hepatitis C-Associated Hepatocellular Carcinoma

Posted Date: Oct 5, 2020

  • Investigator: Shimul Shah
  • Specialties:
  • Type of Study: Observational/Survey

Hepatitis C Virus is the most common cause of Hepatocellular Carcinoma (HCC) in the United States. Liver transplant offers a curative treatment option for early stage HCC meeting Milan criteria. With the emergence of direct acting antivirals (DAAs) there has been improvement in associated morbidity and mortality due to high rates of sustained virologic response. The optimal timing of DAA administration in patients with HCC remains unknown. The goal of our study is to conduct a multi-institutional retrospective review to assess the optimal timing of DAAs for patients with associated HCC who underwent liver transplantation between January 1,2014 - December 31, 2019.


Patients > 18 Years Of Age Who Underwent Liver Transplantation For Hcv-Associated Hcc


Hepatitis C, Hepatocellular Carcinoma, Direct Acting Antivirals

For More Information:

Aaron Delman

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.